



SEMMELWEIS UNIVERSITY
Faculty of Medicine

Department of Pharmacology and Pharmacotherapy

Head: Prof. Péter Ferdinandy, MD, PhD, MBA

Nagyvárad tér 4., Budapest, H-1089 Hungary

Postal address: Üllői út 26., Budapest, H-1085;

P.O. Box 2, Budapest, H-1428

Phone: +36 1 2104416, Fax: +36 1 2104412

E-mail: ferdinandy.peter@med.semmelweis-univ.hu

pharmacology@med.semmelweis-univ.hu

May 10, 2016

To: Council on Basic Cardiovascular Science, ESC

Dear Council members,

I hereby express my interest to serve CBCS as vice-chairperson.

My career has been devoted to basic and translational cardiovascular sciences since the beginning of my medical education. The main fields of interest of mine are molecular mechanisms and translational aspects of cardioprotection in the presence of co-morbidities. I have been listed on the 2014 Highcited Researchers list (for details see brief CV with links to publications and citations).

After joining the Hungarian Society for Cardiology more than 2 decades ago I became actively involved in ESC and the International Society for Heart Research (ISHR). I was president-elect, president, and past-president of ISHR European Section in the period of 2010-2016, and currently I serve ESC as the chairperson of the Working Group and Cellular Biology of the Heart. Moreover, I am happy to be one of the local organizers of FCVB 2020 in Budapest.

Based on my experience in basic and translation sciences in the last 25 years as well as my management experience as chair of a Working Group of ESC, president of ISHR European Section, and founder and chief executive officer of small biotech companies, it would be a great honour for me to further promote basic and translational science as a vice-chairperson of CBCS. In addition to continue the significant achievements CBCS reached so far within ESC, my major plans for the future include increasing the success of FCVB meetings in accordance with the special needs of the working groups and sister societies, and to secure finances of CBCS by promoting collaborations with the “small biotech world” that is especially interested in early-stage developments in cardiovascular therapy.

Péter Ferdinandy



CURRICULUM VITAE OF PETER FERDINANDY

Name: Péter Ferdinandy, MD, PhD, MBA
Birth date: 1966, Hungary
Citizenship: Hungarian
Address: Department of Pharmacology and Pharmacotherapy, Semmelweis University,
Nagyvárad tér 4, Budapest, 1089 Hungary, European Union
e-mail: peter.ferdinandy@pharmahungary.com

Education, scientific degrees:

2004 DSc in medical sciences, Hungarian Academy of Sciences
2000-2004 MBA (Masters of Business Administration, Finance and Quality management), Budapest Technical University, Hungary
1999 Designation as registered Clinical-Pharmacologist
1997-1999: Postdoctoral training, Dept Pharmacology, University of Alberta, Edmonton, Canada
1995 December: PhD in biochemistry (score: excellent, "summa cum laude")
1991-1995: PhD training, Departments of Physiology and Biochemistry, University of Szeged, Hungary
1991 September: MD diploma (score: excellent, "summa cum laude")
1985-1991: University of Szeged, Hungary

Current Positions:

2011-present: Director, Department of Pharmacology and Pharmacotherapy, Medical Faculty, Semmelweis University, Budapest, Hungary. (www.semmelweispharma.com)
2005-present: Professor of Biochemistry (part-time), Head of the Cardiovascular Research Group, University of Szeged, Hungary (www.cardiovasc.com),
2003-present: founder and CEO of Pharmahungary Group (www.pharmahungary.com), Szeged, Hungary (spin-off companies)

Teaching experience:

2004- Lecturer in Pharmacology, Semmelweis University, Budapest
1993- Lecturer in Biochemistry, University of Szeged, Hungary
1998-1999 Lecturer in Pharmacology, University of Alberta, Edmonton, Canada
1991-1994: Lecturer in Physiology, University of Szeged, Hungary

Scholarships, fellowships:

1989-1991: Scholarship of Hungarian Republic
1997-1999: Postdoc Fellow, MRC Canada, University of Alberta, Canada
2001-2005 Szechenyi professorship, Hungarian Academy of Sciences
2013-2014 Szentagothai professorship, National Excellence Program

Major awards:

First prize, Young Investigator Award 1999, International Society for Heart Research

Major leadership positions at international scientific organizations:

President (2012-2014), International Society for Heart Research, European Section
Chairman (2014-2016), Working Group Cell Biology of the Heart, European Cardiology Society

Editorial board memberships:

Br J Pharmacol, J Mol Cell Cardiol, Basic Res Cardiol, J Pharmacol Toxicol Methods

Languages:

Native language: Hungarian
English (fluent), German (basic understanding)

Scientometric data:

Number of papers in international peer-reviewed journals: 171 (source: [PubMed](https://pubmed.ncbi.nlm.nih.gov/))
Cumulative impact factor of full papers: over 650
Total number of citations: over 7500, Hirsch index: 45 (source: [Google Scholar](https://scholar.google.com/))
International Patents: 5
Listed on [HIGHLYCITED 2014](#) (list of the most influential "highly cited" scientists)